Shattuck Labs, Inc. $STTK Shares Bought by Renaissance Technologies LLC

Renaissance Technologies LLC increased its holdings in Shattuck Labs, Inc. (NASDAQ:STTK) by 77.4% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 604,500 shares of the company’s stock after purchasing an additional 263,800 shares during the quarter. Renaissance Technologies LLC’s holdings in Shattuck Labs were worth $3,887,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Virtu Financial LLC bought a new stake in Shattuck Labs during the third quarter worth approximately $38,000. AQR Capital Management LLC increased its holdings in shares of Shattuck Labs by 265.4% in the first quarter. AQR Capital Management LLC now owns 43,169 shares of the company’s stock valued at $41,000 after buying an additional 31,355 shares in the last quarter. Qube Research & Technologies Ltd acquired a new stake in shares of Shattuck Labs during the 2nd quarter valued at $44,000. Squarepoint Ops LLC acquired a new stake in shares of Shattuck Labs during the 3rd quarter valued at $46,000. Finally, Bridgeway Capital Management LLC lifted its position in shares of Shattuck Labs by 147.5% during the 2nd quarter. Bridgeway Capital Management LLC now owns 92,300 shares of the company’s stock valued at $73,000 after acquiring an additional 55,000 shares during the last quarter. 58.74% of the stock is owned by institutional investors and hedge funds.

Shattuck Labs Stock Performance

Shattuck Labs stock opened at $7.27 on Friday. Shattuck Labs, Inc. has a 52 week low of $0.71 and a 52 week high of $8.33. The firm has a market capitalization of $557.46 million, a price-to-earnings ratio of -11.54 and a beta of 1.08. The company has a 50 day moving average price of $6.19 and a 200 day moving average price of $5.85.

Shattuck Labs (NASDAQ:STTK) last announced its earnings results on Thursday, May 7th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.01. During the same quarter last year, the company earned ($0.27) EPS. Equities analysts forecast that Shattuck Labs, Inc. will post -0.5 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on STTK. Citigroup upgraded Shattuck Labs from a “neutral” rating to a “buy” rating and set a $7.00 target price on the stock in a report on Friday, June 5th. Wedbush upped their target price on Shattuck Labs from $8.00 to $11.00 and gave the company an “outperform” rating in a report on Friday, May 8th. Jefferies Financial Group upgraded Shattuck Labs to an “outperform” rating and set a $7.00 price target for the company in a research report on Friday, June 5th. Wall Street Zen raised Shattuck Labs from a “hold” rating to a “buy” rating in a research note on Saturday, June 13th. Finally, JPMorgan Chase & Co. assumed coverage on Shattuck Labs in a report on Friday, July 24th. They set an “overweight” rating and a $10.00 price objective on the stock. Ten research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $12.62.

Insider Activity

In related news, insider Arundathy N. Pandite sold 30,000 shares of the stock in a transaction dated Tuesday, May 12th. The stock was sold at an average price of $6.61, for a total value of $198,300.00. Following the completion of the sale, the insider directly owned 166,219 shares of the company’s stock, valued at approximately $1,098,707.59. This represents a 15.29% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Clay B. Siegall acquired 62,500 shares of the firm’s stock in a transaction on Tuesday, June 9th. The shares were acquired at an average price of $4.00 per share, with a total value of $250,000.00. Following the completion of the transaction, the director directly owned 318,608 shares in the company, valued at approximately $1,274,432. This trade represents a 24.40% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last quarter, insiders have sold 85,907 shares of company stock worth $591,850. 8.79% of the stock is owned by corporate insiders.

About Shattuck Labs

Shattuck Labs, Inc (NASDAQ: STTK) is a clinical?stage biotechnology company headquartered in Cambridge, Massachusetts. The company is focused on developing immunotherapeutic vaccines to prevent and treat substance use disorders, with an initial emphasis on opioids. Shattuck Labs employs a proprietary hapten?carrier conjugate technology designed to generate high?affinity drug?specific antibodies that sequester target molecules in the bloodstream and reduce their passage across the blood?brain barrier.

The company’s lead program targets fentanyl, a synthetic opioid responsible for a significant proportion of overdose fatalities.